Edwards Lifesciences revenue and financials

EW · NYSE · USD

$86.48Change from previous close: −0.86%Absolute change: −$0.75

Close · October 6, 2026

In the fiscal year ended December 2025, Edwards Lifesciences reported revenue of $6.07B (+11.55% year over year). Net income was $1.07B, a net margin of 17.7%.

Annual revenue · 2025: $6.07B
  1. $2.96B2016
  2. $3.44B2017
  3. $3.72B2018
  4. $4.35B2019
  5. $4.39B2020
  6. $5.23B2021
  7. $4.46B2022
  8. $5.01B2023
  9. $5.44B2024
  10. $6.07B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+11.55%
2025 vs 2024
Net income growth
−74.28%
2025 vs 2024
Net margin
17.7%
2024: 76.7%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Annual
Item2025202420232022202120202019201820172016
Total assets13,69713,0559,3638,2938,5037,2376,4885,3245,6964,510
Current assets6,7396,2854,0363,0963,1813,0912,9842,2872,5322,240
Cash and equivalents2,9383,0451,1447698631,1831,179714818930
Short-term investments1,288931501446604—————
Receivables912727828699665—————
Inventory1,1261,087904876727—————
Net property, plant and equipment1,9151,7841,6751,7251,639—————
Goodwill1,7691,7771,2541,0651,1681,1731,1681,1121,127626
Other intangible assets1,1281,177399285324—————
Long-term investments2793085841,2391,834—————
Current liabilities1,8141,5051,1951,0221,0328949028771,403533
Accounts payable228197187202205—————
Long-term debt598598597596596595594594438822
Total debt705700685691——————
Total liabilities3,3602,9922,6442,4862,667—————
Total equity (incl. minority)10,33810,0636,7195,8075,836—————
Retained earnings14,24113,1678,9927,5906,068—————
Minority interest0.064.569.40.0——————